Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

On April 8, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, reported the presentation of two poster presentations at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting reporting new preclinical data that support the company’s preclinical TREX1 and clinical TPST-1495 programs (Press release, Tempest Therapeutics, APR 8, 2022, View Source [SID1234611671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first presentation reports on new preclinical data that support TPST-1495, a novel agent designed to specifically block the cancer-promoting EP2 and EP4 prostaglandin E2 (PGE2) receptors, further differentiating TPST-1495 from other approaches targeting the PGE2 pathway. The second presentation reports on proprietary inhibitors of TREX1, a cytosolic DNA exonuclease that inhibits activation of cGAS/STING in tumor and immune cells.

"As part of our diversified pipeline of innovative therapeutics, we reported the first preclinical data from our TREX1 program demonstrating the significant anti-tumor activity of our selective inhibitors. We believe TREX1 is the most promising approach to selectively activate the STING pathway broadly in metastatic disease with systemically administered, small molecule drugs," said Tom Dubensky, Ph.D., president of Tempest. "In addition, we presented preclinical data demonstrating that selective dual antagonism of both EP2 and EP4 prostaglandin receptors with TPST-1495 is a significantly superior approach to provide therapeutic anti-tumor benefit and activate human immune cell populations in vitro, as compared to either single EP2 and EP4 antagonists or NSAIDs. These data support the enthusiasm for our ongoing Phase 1 monotherapy and combination dose escalation and optimization study."

#1333: "Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway"

In vivo data demonstrated that monotherapy TPST-1495 significantly reduced tumor growth in mice via both T cell-independent and T-cell dependent mechanisms. The anti-tumor effect correlated with direct anti-proliferative effects on tumors in addition to increased tumor infiltration by NK cells, CD8+ T cells, AH1-specific CD8+ T cells, and other anti-tumor myeloid and adaptive immune cell populations. Demonstrating its differentiated potency, therapy with TPST-1495 resulted in a significant survival advantage as compared to therapy with single EP2 or EP4 antagonists, or the NSAID celecoxib, in the APCmin/+ spontaneous colorectal cancer tumor mouse model. Additional data demonstrated that the administration of TPST-1495 resulted in near-complete restoration of immune function in human immune cell assays, reversing prostaglandin-mediated suppression of lipopolysaccharide stimulation-induced TNF-α production, even in the presence of elevated PGE2 concentrations in which single EP4 or EP2 inhibitors were not effective.

#2075: "Systemic Small Molecule TREX1 Inhibitors to Selectively Activate STING in the TME of Metastatic Disease"

The inaugural presentation for the TREX1 program summarized the approach to develop selective TREX1 inhibitor small molecules with picomolar potency. TREX1 inhibitors were profiled in various human and mouse cell-based assays, demonstrating that inhibition of TREX1 nuclease activity resulted in increased cGAS/STING pathway signaling and production of a reporter or interferon β. The anti-tumor activity of TREX1 inhibitors was evaluated in mice given sub-therapeutic doses of doxorubicin to effect double-stranded breaks in tumor cell DNA and induce the production of TREX1, resulting in significant anti-tumor efficacy and survival.

About TPST-1495

TPST-1495 is an orally available small molecule designed to block the cancer-promoting EP2 and EP4 receptors in the prostaglandin (PGE2) pathway, while sparing the homologous but differentially active EP1 and EP3 receptors. PGE2 signaling through EP2 and EP4 has been observed to enhance tumor progression through the stimulation of tumor proliferation, enhanced angiogenesis and suppression of immune function in the tumor microenvironment. Tempest has conducted head-to-head preclinical studies comparing TPST-1495 to single antagonists of EP2 and EP4 and observed significantly enhanced activity of TPST-1495 in both overcoming PGE2-mediated suppression of human immune cells in vitro, as well as significantly increased anti-tumor activity in mouse models of human colorectal cancer. Tempest is currently evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and possible anti-tumor activity of monotherapy and combination therapy TPST-1495 in a multicenter Phase 1a/1b dose and schedule optimization study in subjects with advanced solid tumors, with the potential to expand in indications known to be prostaglandin-driven, including colorectal cancer, or CRC, and in a tumor indication-agnostic, biomarker-selected cohort.

About TREX1

Genetic evidence from human disease and mouse genetic knock-out studies identify the Stimulator of Interferon Genes (STING) pathway as a critical innate immune sensor for the development of immunity. Tumor cells can evolve to avoid immune recognition through inactivating the STING pathway by diverse mechanisms, indicating that it is important to generating tumor-specific immunity. Selective activation of the STING pathway may be achieved through targeted inhibition of TREX1, a cytosolic DNA exonuclease that modulates cGAS/STING signaling, which is overexpressed in tumor cells. Tempest is developing TREX-1 inhibitors with oral pharmacokinetics. In vitro and in vivo studies have shown that the company’s compounds enhance the activation of the STING pathway in DNA-stimulated human and mouse cells. Furthermore, preclinical results in several tumor models have shown synergies of its TREX-1 compounds with low doses of doxorubicin, demonstrating significant therapeutic anti-tumor efficacy and survival.

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

On April 8, 2022 Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, reported its presentation of preclinical data for both ONCR-021 and ONCR-788 in two e-posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana, supporting the company’s selectively self-amplifying viral RNA (vRNA) Immunotherapy Platform (Press release, Oncorus, APR 8, 2022, View Source [SID1234611670]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The preclinical data presented on ONCR-021 and ONCR-788 at AACR (Free AACR Whitepaper) are an important step forward for Oncorus’ novel approach of selectively self-amplifying vRNA immunotherapies formulated in lipid nanoparticles. We are incredibly pleased to see these vRNA drug candidates’ potent efficacy in preclinical tumor models, after intravenous administration of the nanoparticle formulation even in the presence of neutralizing antibodies," said Ted Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "These data further bolster our confidence in our vRNA platform’s ability to deliver the RNA genome of oncolytic viruses to tumors intravenously and to circumvent the common limitation of existing IV-administered oncolytic viral cancer therapies. We look forward to advancing this next-generation approach of selectively self-amplifying vRNA, furthering our goal of realizing the full potential of systemically active viral immunotherapies to transform outcomes for cancer patients."

Oncorus’ vRNA Immunotherapy Platform encapsulates the genomes of RNA viruses known to kill cancer cells within an LNP, producing a living oncolytic and immunostimulatory viral infection in the tumor to destroy cancer cells and stimulate the immune system. In preclinical studies, Oncorus’ IV-administered vRNA immunotherapies demonstrated efficacy in multiple tumor models, avoiding the challenges seen in previous studies incorporating IV administration of RNA-based oncology therapeutics.

In a poster titled, "ONCR-021 as a systemic intravenous synthetic RNA virus immunotherapy for the repeat treatment of cancer," Oncorus highlighted:

ONCR-021, Oncorus’ lead vRNA immunotherapy product candidate, is an LNP formulation of Coxsackievirus A21 (CVA21) vRNA, which encodes an optimized strain of CVA21.
ONCR-021 demonstrated greater in vitro and in vivo oncolysis compared to previously described CVA21 Kuykendall strain.
IV administration of ONCR-021 vRNA resulted in rapid initiation of viral replication, oncolysis and potent anti-tumor efficacy driven by CVA21 amplification in situ after delivery to tumor cells.
Preclinical data support the potential clinical development of ONCR-021 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma based on viral tropism.
Oncorus plans to submit an investigational new drug (IND) application for ONCR-021 with the U.S. Food and Drug Administration (FDA) in mid-2023.

In a poster titled, "Development of ONCR-788, a synthetic oncolytic virus based on Seneca Valley Virus for the treatment of neuroendocrine tumors," Oncorus highlighted:

ONCR-788, Oncorus’ second vRNA immunotherapy product candidate, encodes an optimized version of the Seneca Valley Virus (SVV).
Systemic IV administration of ONCR-788 led to potent anti-tumor efficacy, even in the presence of oncolytic virus neutralizing antibodies within the bloodstream.
vRNA delivery, viral replication, spread and lysis of tumor cells were observed after administration of ONCR-788.
Robust anti-tumor efficacy was observed across a diverse set of neuroendocrine tumor models, including tumor CDX and PDX xenografts, lung orthotopic and GEMM-derived models.
Enhanced T cell recruitment and activation, increased expression of PD-L1 on tumor cells and myeloid cells and M2 to M1 macrophage conversion were observed.
ONCR-788 in combination with an anti-PD1 resulted in improved anti-tumor activity as compared to ONCR-788 monotherapy.
Oncorus plans to submit an IND for ONCR-788 with the FDA following the IND submission for ONCR-021.

The posters presented at AACR (Free AACR Whitepaper) are available on the "Publications & Presentations" section of the Oncorus website at www.oncorus.com.

OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR

On April 8, 2022 OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, reported preclinical data demonstrating synergy between OKI-179, the Company’s oral Class I histone deacetylase (HDAC) inhibitor, and RAS pathway agents, including Pfizer’s MEK inhibitor, binimetinib, in RAS-mutated tumor models (Press release, OnKure, APR 8, 2022, View Source;utm_medium=rss&utm_campaign=onkure-therapeutics-announces-promising-preclinical-data-on-oki-179-in-ras-mutated-tumor-models-presented-in-a-late-breaking-session-at-aacr [SID1234611669]). The data will be disclosed in a late-breaking abstract during the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held in New Orleans, Louisiana from April 8, 2022 to April 13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The preclinical data highlighting our HDAC inhibitor’s synergy with RAS pathway agents are extremely promising, and based on the anti-tumor activity seen, strongly support the clinical development of this combination across multiple indications, including in cancer types less sensitive to RAS pathway inhibition alone," said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure. "OKI-179 has been designed to overcome the historic tolerability limitations of other HDAC inhibitors, supporting further development in rational combinations with other anti-cancer treatments. Since inhibition of the RAS pathway alone through MEK or BRAF inhibitors is often insufficient to drive tumor regression, it opens an opportunity for combination approaches with OKI-179, with the potential to establish this candidate as a backbone therapy for all RAS-mutated cancers."

The data, both in vitro and in vivo, showcase the potential of the synthetically lethal combination of OKI-179 and RAS pathway agents in treating RAS-mutated tumors. In cell-line derived xenograft models, OKI-179, binimetinib as a single agent, and binimetinib + encorafenib combination demonstrated tumor growth delay, but few regressions. OKI-179 combined with binimetinib in NRAS-mutated melanoma or combined with binimetinib + encorafenib in BRAF-mutated colorectal xenografts showed significantly increased regressions compared to either single agent following two weeks of dosing.

Jennifer Diamond, M.D., OnKure’s Chief Medical Officer said, "We plan to initiate the Nautilus trial, which will explore the combination of OKI-179 and binimetinib in advanced NRAS-mutated melanoma, and look forward to continuing to validate this synthetically lethal combination across cancer types in order to fully understand its potential as a therapeutic approach."

The poster presentation from the AACR (Free AACR Whitepaper) Annual Meeting is available on the "Publications" page of the Company’s website at View Source

About NRAS-Mutated Melanoma

Activating mutations in NRAS is the second most common oncogenic driver in melanoma, accounting for 20% of all melanomas. Tumors bearing NRAS mutations are more aggressive and are associated with poorer patient outcomes. Despite the prevalence of NRAS mutations and the severity of the resulting disease, treatment options for NRAS-mutated melanoma remain limited for patients who have disease progression following immune checkpoint inhibitor therapy, highlighting the significant unmet need.

About OKI-179

OKI-179 is a novel, oral Class I histone deacetylase (HDAC) inhibitor for the potential treatment of a wide range of solid and hematological malignancies. HDAC inhibitors have shown little activity in treating solid tumors, often due to poor tolerability, inappropriate dosing regimens, and a lack of stratifying biomarkers. OKI-179 is designed to have improved potency, selectivity, tolerability, as well as easy combinability to overcome the historic limitations of other HDAC inhibitors. This candidate has also shown a promising safety profile in advanced solid tumor patients, supporting potential combination studies in the future.

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

On April 8, 2022 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 8-13, 2022 in New Orleans, LA (Press release, Bicycle Therapeutics, APR 8, 2022, View Source [SID1234611668]). The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details

Title: BT8009-100 Phase I/II Study of Novel Bi-Cyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression
Abstract #: CT025
Presenter: Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Biomarker Advances in Clinical Trials
Date/Time: Sunday, April 10, 2022 at 4:05 – 4:15 p.m. CT

The abstract can now be viewed here.

Conference Call Details

Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m. ET to review the data being presented. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.

Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1

On April 8, 2022 Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), reported that preclinical data for ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancers, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2022 (Press release, Orum Therapeutics, APR 8, 2022, View Source [SID1234611667]). ORM-5029 is one of two lead programs from the company’s Antibody neoDegrader Conjugate (AnDC) platform based on its Dual-Precision Targeted Protein Degradation (TPD²) approach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORM-5029 is designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting. Orum developed a proprietary class of GSPT1 degrader molecules, paired them with a HER2-targeting antibody, pertuzumab, and screened numerous candidate conjugates to identify a molecule with the desired therapeutic profile. The data presented at AACR (Free AACR Whitepaper) 2022 describes initial preclinical evaluation of potency, efficacy, and pharmacodynamic (PD) response of ORM-5029.

"Targeted protein degradation holds much therapeutic promise, but classic TPD approaches face clinical development hurdles, including optimizing potency, exposure, and tolerability," said Peter U. Park, Ph.D., Chief Scientific Officer of Orum Therapeutics. "We believe that we can fulfill the promise of TPD by developing novel small molecule degraders combined with the precise cellular delivery mechanism of antibodies. Compared to either small molecule GSPT1 degraders or standard-of-care antibody drug conjugates, ORM-5029 exhibited superior in vitro and in vivo potency, robust efficacy in low-HER2 settings, and dose-dependent efficacy. These data provide compelling evidence to support our unique approach to targeted protein degradation and continue development of ORM-5029."

Key data takeaways:

ORM-5029 displays robust efficacy both in vitro and in vivo compared to other small molecule GSPT1 degraders and approved antibody drug conjugates (ADCs)

ORM-5029 exhibits potent activity in HER2-low models both in vitro and in vivo

Dose-dependent efficacy of ORM-5029 correlates with robust and rapid PD modulation of tumor GSPT1 protein levels

Orum’s proprietary payload, SMol006, is a potent degrader with high selectivity for GSPT1 and is compatible with any ADC linker and conjugation technologies.

AACR 2022 is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13. The poster presentation titled, "ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer," will be available for viewing to registered attendees from Friday, April 8, through Wednesday, July 13, on the AACR (Free AACR Whitepaper) Annual Meeting 2022 website. The poster (abstract # 3933) will be presented in person on April 13 from 9:00 am to 12:30 pm in Session PO.ET06.06 – Emerging New Anticancer Agents in Exhibit Halls D-H, Poster Section 22, Poster Number 7.

The poster is available on request; please email us at [email protected].

About Orum’s AnDC Platform

Orum’s Antibody neoDegrader Conjugate (AnDC) platform uses the Company’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach to build novel targeted protein degraders (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death.